Navigation Links
Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Research's 100th Annual Meeting

-- Phase 1 Data from Colorectal Cancer and Oral Picoplatin Trials To Be Presented --

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present final data from two Phase 1 clinical trials of picoplatin, the Company's lead product candidate, at poster sessions during the American Association for Cancer Research 100th Annual Meeting 2009 at the Colorado Convention Center in Denver. The Company will present efficacy and safety data from its Phase 1 trial of picoplatin in colorectal cancer (CRC) and bioavailability data from its Phase 1 trial of an oral formulation of picoplatin.

    Details are as follows:

    A Phase 1 study of picoplatin in combination with 5-fluorouracil and
    leucovorin (FOLPI) for colorectal cancer (CRC): Comparison of two
    picoplatin schedules
    Abstract #3578
    Earhart R, Gladkov OA, Cheporov SV, Biakhov MY, Manikhas B, Berdov B,
    Tjulandin S, Breitz H, De Jager R.
    Tuesday, April 21, 8:00 a.m. MDT
    Clinical Research 11 Session
    Hall B-F, Poster Section 30

    A Phase 1 randomized crossover oral picoplatin bioavailability
    pharmacokinetics and pharmacodynamics study
    Abstract #3594
    Phillips A, Saleh M, Yee L, Sharma S, Houston S, Karlin D, Breitz H,
    DeJager R, Earhart R.
    Tuesday, April 21, 8:00 a.m. MDT
    Clinical Research 12
    Hall B-F, Poster Section 31

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic 2 colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
(Date:10/12/2015)... Oct. 12, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... engaged in developing and commercializing novel treatments in oncology, ... Dennis Turpin , the Company,s former Senior Vice ... its Quebec City office.  ... Chief Executive Officer of the Company commented, "After a ...
(Date:10/12/2015)... PHILADELPHIA , October 12, 2015 ... alternative to print version for enriched online experience ... media alternative to print version for enriched online ... offers user-friendly, multi media alternative to print version ... a world-leading provider of scientific, technical and medical information ...
(Date:10/12/2015)... ... , ... NeuMedics Inc., is a specialty biopharmaceutical company focused on identifying and ... be administered as an eye drop, announced today it has been selected to present ... place October 25th to October 28th at The Cleveland Clinic, Cleveland, Ohio. The ...
(Date:10/10/2015)... , le 10 octobre 2015 Le 8 octobre, ... intégré dans le Registre du Congrès sa déclaration ... pour la sensibilisation autour du plasma (IPAW), qui ... sponsorisée par la Plasma Protein Therapeutics Association ... à : , Sensibiliser l,opinion publique ...
Breaking Biology Technology:
(Date:10/8/2015)... Connecticut , October 8, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company ... creator of the Wocket® smart wallet announces that ... 2015 were approximately $410,000 compared with $113,00 for ... for the 9 months ended September 30, 2015 ...
(Date:10/6/2015)... , Oct. 6, 2015 Track Group, Inc. ... that it has signed a contract with the Virginia ... the full range of sentences under the Department,s oversight. ... the Americas. "This contract with the Virginia DOC will ... US and advances our position as a trusted leader ...
(Date:10/2/2015)... Oct. 02 2015 ... "Enforcing the Law Using Biometrics" report ... has announced the addition of the "Enforcing ... offering. --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report ...
Breaking Biology News(10 mins):